SECsense Logo

Protagenic Therapeutics, Inc. 8-K Report: Insights for Investors (Jan 2025)

$PTIX
Form 8-K
Filed on: 2025-01-10
Source
Protagenic Therapeutics, Inc. 8-K Report: Insights for Investors (Jan 2025)

Based on the provided section of the financial report, here are the key pieces of information and insights extracted:

  1. Entity Information:
  • Company Name: Protagenic Therapeutics, Inc.
  • CIK Number: 0001022899
  • Address: 149 Fifth Avenue Suite 500, New York, NY 10010
  • Phone Number: 212-994-8200
  • SEC Filing Type: 8-K
  • Filing Date: January 9, 2025
  1. Stock Information:
  • Common Stock Ticker: PTIX (NASDAQ)
  • Common Stock Warrants Ticker: PTIXW (NASDAQ)
  1. Reporting Period:
  • The report is for a single date, January 9, 2025.
  1. Financial Metrics:
  • The reporting units used are USD (United States Dollar) and Shares.
  • There are explicit members for common stock and common stock warrants, indicating possible separate financial line items or categories.
  1. Key Contexts:
  • There are specified contexts for the common stock and common stock warrants, which suggests that the financial data may provide insights into the performance or position of these instruments specifically on the reporting date.
  1. Schema Reference:
  • The report references a schema file ptix-20250109.xsd, indicating it adheres to specific XBRL standards for reporting.

Insights:

  • The report indicates that Protagenic Therapeutics, Inc. is actively maintaining its compliance with SEC reporting requirements, especially with the 8-K filing.
  • The mention of both common stock and warrants suggests that the company may be involved in capital-raising activities or has obligations tied to these instruments.
  • The filing date and the nature of the report suggest that it might contain significant or current developments affecting the company's stock, which could be of interest to investors and stakeholders.

This information can be useful for investors, analysts, and stakeholders who are tracking the performance and regulatory compliance of Protagenic Therapeutics, Inc.